Mabpharm Limited (HKG:2181)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
0.4000
0.00 (0.00%)
May 28, 2026, 2:55 PM HKT
Market Cap1.65B -7.0%
Revenue (ttm)718.98M +150.2%
Net Income63.58M
EPS0.01
Shares Out 4.12B
PE Ratio35.95
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume62,000
Open0.4000
Previous Close0.4000
Day's Range0.4000 - 0.4000
52-Week Range0.4000 - 0.8800
Beta0.61
Analystsn/a
Price Targetn/a
Earnings DateJun 4, 2026

About Mabpharm

Mabpharm Limited, a biopharmaceutical company, engages in research, development, production, and commercialization of drugs and biosimilar for cancers and autoimmune diseases in the People’s Republic of China. The company offers CMAB007, a recombinant humanized anti-immunoglobulin E monoclonal antibody for treatment of asthma patients; CMAB009, a recombinant anti-EGFR chimeric monoclonal antibody for the first-line treatment of metastatic colorectal cancer; and CMAB008, a recombinant anti-TNF-alpha chimeric monoclonal antibody for the treatment... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2018
Employees 389
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2181
Full Company Profile

Financial Performance

Financial numbers in CNY Financial Statements